

2024
HOSPITAL RECOGNITION CRITERIA
(based on 2023 data)

ACHIEVEMENT MEASURES >85% OR GREATER




2 consecutive calendar years



1 calendar year



1 calendar quarter and ≥30 patients



QUALITY MEASURES + AWARD

≥75% on at least 4 measures

*Must achieve Silver or Gold to be eligible

Dysphagia Screening (AHA STR8)

Stroke Education (AHA STR12)

Assessed for Rehabilitation (AHA STR11)

LDL Documented (AHA STR9)

NIHSS Reported (AHA STR10)

Door to Needle ≤60 minutes (AHA STR13)



TARGET: STROKE

(Minimum of 6 patients to be eligible)

HONOR ROLL

75% of applicable patients (AHA STR13)

Door-to-Needle ≤60 minutes

HONOR ROLL ELITE

85% of applicable patients (AHA STR13)

Door-to-Needle ≤60 minutes

HONOR ROLL ELITE PLUS

75% of applicable patients & 50% of applicable patients
Door-to-Needle ≤45 minutes (AHA STR49) & Door-to-Needle ≤30 minutes (AHA STR48)

HONOR ROLL ADVANCED THERAPY

50% of applicable patients

Door-to-Device ≤90 minutes for Direct Arriving Patients (AHA STR114) & ≤60 minutes for Transfer Patients (Within 6 hours or 24 hours) (AHA STR114)



American Heart Association.
Target: Type 2 DiabetesSM

2024
HOSPITAL RECOGNITION CRITERIA
(based on 2023 data)

THE AWARD REPORTING PERIOD MUST:

- 1** Be the same calendar year as your eligible achievement award
- 2** Include the same patient population as is included in the eligible achievement award



American Heart Association.
Get With The Guidelines.
Stroke



American Heart Association.
Get With The Guidelines.
Coronary Artery Disease



American Heart Association.
Get With The Guidelines.
Heart Failure

Hospital Must Qualify for Silver Level or Higher Achievement Award

≥10 Patients with a New Onset or Previous History of Diabetes

Overall Diabetes Cardiovascular Initiative Composite Score (AHASTR150) criteria:
≥ 80% Compliance for 12 Consecutive Months (Calendar Year)

IV Thrombolytics Arrive by 3.5 hours / Treat by 4.5 hours (AHASTR149)

Early Antithrombotics for Patients With Diabetes (AHASTR148)

VTE Prophylaxis (AHASTR154)

Antithrombotic Prescribed at Discharge (AHASTR145)

Anticoagulation Prescribed for AFib/AFlutter at Discharge (AHASTR144)

Smoking Cessation (AHASTR151)

Intensive Statin Prescribed at Discharge (AHASTR298)

Diabetes Treatment (AHASTR130)

Therapeutic Lifestyle Changes (TLC) Recommendations at Discharge (AHASTR153)

Antihyperglycemic Medication With Proven CVD Benefit (AHASTR146)

Overall Diabetes Cardiovascular Initiative Composite Score (AHACAD73) criteria:
≥ 75% Compliance for 12 Consecutive Months (Calendar Year)

ACE-I or ARB for LVSD at Discharge for Patients with Diabetes (AHACAD66)

Adult Smoking Cessation Advice for Patients with Diabetes (AHACAD67)

Antihyperglycemic Medication with Proven CVD Benefit (AHACAD74)

Aspirin at Discharge for Patients with Diabetes (AHACAD68)

Beta-Blocker at Discharge for Patients with Diabetes (AHACAD69)

Cardiac Rehabilitation Patient Referral from an Inpatient Setting (AHACAD70)

Dual Antiplatelet Therapy Prescribed at Discharge (AHACAD71)

High-Intensity Statin at Discharge (AHACAD72)

Overall Diabetes Cardiovascular Initiative Composite Score criteria:
≥ 75% Compliance for 12 Consecutive Months (Calendar Year)

ACEI/ARBs or ARNI at Discharge (AHAHF77)

Evidence-Based Beta Blocker Prescribed at Discharge (AHAHF78)

Post-Discharge Appointment Scheduled (AHAHF80)

Smoking Cessation (AHAHF82)

Left Ventricular Function Assessed (AHAHF79)

Lipid-Lowering Medication Prescribed at Discharge (AHAHF81)

Diabetes Treatment (AHAHF26)

Antihyperglycemic Medication With Proven CVD Benefit (AHAHF84)